Zonisamide for prevention of Atypical (Second generation) antipsychotics associated weight gain in schizophrenia : A double blind, placebo controlled trial.
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Zonisamide (Primary)
- Indications Weight gain
- Focus Therapeutic Use
- 15 Aug 2013 Status changed from active, no longer recruiting to completed.
- 01 Jun 2013 Primary endpoint 'Body-mass-index' has been met.
- 01 Jun 2013 Primary endpoint 'Bodyweight' has not been met.